Yat Or Biography and Net Worth

Dr. Or joined Enanta in November 1999 and led its preclinical and early clinical development efforts, including the team responsible for achieving all milestones in the collaboration with AbbVie to develop hepatitis C treatments. Dr. Or and his team discovered glecaprevir, the protease inhibitor in AbbVie’s successful combination treatment for hepatitis C virus currently marketed as MAVYRET^®. He is leading Enanta’s ongoing research for virology and immunology. Dr. Or’s team also worked on the earlier protease inhibitor in AbbVie’s VIEKIRA PAK^® treatment for hepatitis C virus, and previously developed antibacterials for methicillin-resistant staphylococcus aureus (MRSA). Further, Dr. Or has managed Enanta’s research and development collaborations with Shionogi, Abbvie and Novartis.

Prior to Enanta, Dr. Or was a senior project leader and research fellow of antibacterial research at Abbott Laboratories from 1985 to 1999. Prior to Abbott, he was a member of the cardiovascular drug discovery team at Schering-Plough.

Dr. Or received his Ph.D. in Organic Chemistry from the University of Chicago and completed Postdoctoral Fellowships at Ohio State University and Indiana University. He has co-authored more than 100 publications and is listed as a co-inventor on over 260 filed U.S. patent applications.

What is Yat Sun Or's net worth?: The estimated net worth of Yat Sun Or is at least $5.09 million as of December 5th, 2025. Or owns 371,392 shares of Enanta Pharmaceuticals stock worth more than $5,093,641 as of April 28th. This net worth evaluation does not reflect any other assets that Or may own. Learn More about Yat Sun Or's net worth.
How do I contact Yat Sun Or?: The corporate mailing address for Or and other Enanta Pharmaceuticals executives is 500 ARSENAL STREET, WATERTOWN MA, 02472. Enanta Pharmaceuticals can also be reached via phone at (617) 607-0800 and via email at [email protected]. Learn More on Yat Sun Or's contact information.
Has Yat Sun Or been buying or selling shares of Enanta Pharmaceuticals?: Yat Sun Or has not been actively trading shares of Enanta Pharmaceuticals over the course of the past ninety days. Most recently, Yat Sun Or sold 2,390 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a transaction totalling $34,009.70. Following the completion of the sale, the insider now directly owns 371,392 shares of the company's stock, valued at $5,284,908.16. Learn More on Yat Sun Or's trading history.
Who are Enanta Pharmaceuticals' active insiders?: Enanta Pharmaceuticals' insider roster includes Nathalie Adda (VP), Kathleen Capps (Insider), Tara Kieffer (Insider), Jay Luly (CEO), Brendan Luu (Insider), Paul Mellett, Jr. (Sr. VP of Fin. & Admin. and CFO ), Yat Or (Insider), and Scott Rottinghaus (Insider). Learn More on Enanta Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Enanta Pharmaceuticals?: During the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 11,961 shares worth more than $170,149.14. The most recent insider tranaction occured on December, 5th when insider Kathleen S Capps sold 323 shares worth more than $4,596.29. Insiders at Enanta Pharmaceuticals own 11.5% of the company. Learn More about insider trades at Enanta Pharmaceuticals.
Information on this page was last updated on 12/5/2025.

Yat Sun Or Insider Trading History at Enanta Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/5/2025	Sell	2,390	$14.23	$34,009.70	371,392
3/15/2023	Sell	13,925	$44.45	$618,966.25	374,702
3/1/2019	Sell	10,000	$103.53	$1,035,300.00	304,763
2/11/2019	Sell	27,684	$89.39	$2,474,672.76	320,169
1/4/2017	Sell	13,921	$35.09	$488,487.89	301,876
11/29/2016	Sell	13,921	$31.44	$437,676.24	315,797
7/13/2015	Sell	3,750	$46.29	$173,587.50
6/11/2015	Sell	3,750	$42.47	$159,262.50
6/5/2015	Sell	10,750	$42.02	$451,715.00
5/11/2015	Sell	8,000	$36.13	$289,040.00
5/1/2014	Sell	5,000	$36.98	$184,900.00	184,078
4/1/2014	Sell	10,000	$39.16	$391,600.00	189,078
3/24/2014	Sell	10,000	$39.34	$393,400.00	199,078

Yat Sun Or Buying and Selling Activity at Enanta Pharmaceuticals

Enanta Pharmaceuticals Company Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $13.71

$13.26

$13.78

50 Day Range

MA: $13.55

$12.08

$15.41

2 Week Range

Now: $13.71

$4.96

$17.15

Volume

102,662 shs

Average Volume

182,022 shs

Market Capitalization

$397.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99